Molecular profile of patients with myelofibrosis: a 10-year experience.
Lara Faria Souza DiasCarolina Leme de Moura PereiraNewton de Freitas CenturiãoJade Zezzi Martins do NascimentoAndreza Alice Feitosa RibeiroNelson HammerschlakCarolina Perrone MarquesAna Carolina Vieira de LimaLuana Nóbrega da CostaAnderson Felipe da SilvaViviane de Jesus Torres LimaMariana Nassif KerbauyLucila Nassif KerbauyLeonardo Javier ArcuriPaulo Vidal CampregherJuliana Dall Agnol da RochaTarcila Santos DatoguiaFabio Pires de Souza SantosPublished in: Einstein (Sao Paulo, Brazil) (2023)
The molecular analysis enables estimating the patient's risk and thus instituting more aggressive treatment such as bone marrow transplant for patients at higher risk, being a relevant tool to guide therapy. Given the significance of molecular analysis for therapeutic decision-making in myelofibrosis, collection and disclosure of data on the prevalence of cytogenetic changes and findings of next-generation sequencing in affected patients is important.